Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.

Expert opinion on drug metabolism & toxicology - 1 Aug 2016

Liu Xiaoman, Low Siew-Kee, Boddy Alan V

Abstract excerpt

INTRODUCTION: Breast cancer is the most common female cancer and remains a serious public health concern worldwide. Third-generation aromatase inhibitors (AIs) are widely used in postmenopausal women with estrogen receptor positive breast cancer. However, there is marked interindividual variability in terms of the efficacy and incidence of adverse events following treatment with AIs. Pharmacogenetics has the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genetic Variation

Share to Pharmacogenetics

Share to Postmenopause

Share to Precision Medicine

Share to Receptors, Estrogen

Source

Identifiers

PMID: 27253864
DOI: 10.1080/17425255.2016.1196189

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.PMID 27253864Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer TreatmentSemantic proximity Read ↗

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Semantic proximity Read ↗

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.Semantic proximity Read ↗

No Evidence of Genotype‒Treatment Interactions between Endocrine Therapies and Adverse Drug Effects in Women with Breast Cancer: Findings from the UK BiobankSemantic proximity Read ↗

Significance of the Estrogen Hormone and Single Nucleotide Polymorphisms in the Progression of Breast Cancer among Female.Semantic proximity Read ↗

Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.Semantic proximity Read ↗

Pharmacogenomics in Tailoring First-Line Therapy for Breast Cancer: PharmGKB Database InsightsSemantic proximity Read ↗

Pharmacogenomics in breast cancer: current trends and future directions.Semantic proximity Read ↗

Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.Semantic proximity Read ↗

Genomics and pharmacogenomics of breast cancer: current knowledge and trends.Semantic proximity Read ↗

CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.